Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
(CNBC, 2025-12-11T11:51:30Z)